Lilly And GSK/Vir Antibody Combo Reduces COVID-19 Viral Load
Top-line Phase II data show that a combo of bamlanivimab and VIR-7831, neutralizing antibodies to the SARS-CoV-2 spike protein, yielded a relative 70% reduction in viral load.
You may also be interested in...
The UK wants to consolidate its rapid vaccine roll-out and its domestic supply chain via the alliance
The companies look set to join Lilly and Regeneron once an EUA is secured, but producing enough supplies to meet demand will be the next challenge.
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.